Unmet Need: Bladder cancer is a global disease, with 540,000 incident cases and 188,000 deaths in 2015 worldwide. In the United States 81,190 patients will be diagnosed in 2018 and 17,240 will die from their disease.(1) The first-line treatment of non-muscle-invasive bladder cancer (NMIBC) is the transurethral resection of bladder tumors (TURBT), followed by the intravesical administration of Bacillus Calmette-Guérin (BCG). However, 50% of patients will not respond to BCG therapy and often require the use of conventional chemotherapy delivered intravesically through a catheter. Systemic cisplatin (CDDP)-based chemotherapy is the standard of care for advanced or metastatic bladder cancer. Yet, when conventional CDDP is delivered intravesically, it has toxic side effects and its efficacy is limited by its low penetration of bladder tissue. Consequently, localized, intravesical administration of novel CDDP formulations may have improved efficacy and tolerability compared to systemic administration.
Technology Overview: The inventors have developed a nanoparticle-based CDDP therapy that enhances CDDP’s retention in the bladder. This intravesical formulation of CDDP had decreased bladder toxicity and reduced systemic CDDP exposure compared to standard CDDP administration. Importantly, the CDDP nanoparticles had high anticancer activity in vivo and in vitro.
Stage of Development: This invention has been shown to enhance CDDP retention in the bladder and have reduced toxicity in both mice and rat models. In a rat model of NMIBC, the CDDP nanoparticles reduced the tumor burden significantly.
Inventors: Laura Ensign, Justin Hanes, Max Kates, Trinity Bivacqua, Abhijit Date
Patent Status: Pending US application publication US2020/0009068
Publications: Kates, M et al., Clinical Cancer Research. 2017 Nov 1; (23)21: 6592-6601.
